Biotech’s top money raisers of 2023
Home
Our Approach
Pipeline & Targets
→
← Back
/ Pipeline & Targets /
Pipeline & Targets Overview
Our Pipeline
Nimbus Programs
Acquired Programs
Publications & Presentations
News & Events
Culture & Careers
About Us
→
← Back
/ About Us /
About Us Overview
Nimbus Leadership
Board of Directors
Investors
Contact Us
Nimbus Therapeutics
Archives:
In the News Items
Biotech’s top money raisers of 2023
Nimbus Therapeutics raises $210 million in one of the larger fundraising rounds this year
AI Drug Discovery Is a $50 Billion Opportunity for Big Pharma
AAD 2023 – Takeda outdoes Bristol’s Sotyktu
Takeda’s $4 Billion Psoriasis Pill Helped Clear Skin in Mid-Stage Study
Nimbus hopes to strike thrice
Nimbus CEO Jeb Keiper on negotiating a $4B deal and building an unorthodox biotech startup
In its largest single-asset purchase ever, Takeda snaps up TYK2 drug for $4B upfront
Sunny days for Nimbus: Lilly inks $496M biobucks deal for potential metabolic disease therapies
Nimbus Therapeutics raises $125m to test drug in psoriasis, lupus, and other diseases
Posts navigation
Page
1
Page
2
…
Page
4
Next page